药石科技(300725) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥335,643,580.55, representing a year-over-year increase of 17.44% compared to ¥285,807,823.32 in the same period last year[3] - Net profit attributable to shareholders was ¥70,839,845.23, a slight increase of 1.53% from ¥69,771,989.47 in the previous year[3] - Net profit for the current period was ¥74,367,424.72, representing a 6.3% increase from ¥69,771,813.76 in the previous period[32] - Total operating revenue for the current period reached ¥335,643,580.55, an increase of 17.4% compared to ¥285,807,823.32 in the previous period[29] - Total operating costs amounted to ¥254,700,510.42, up 15.5% from ¥220,439,922.16 in the prior period[29] - The total comprehensive income attributable to the parent company was 70,600,622.80, compared to 69,827,416.06 in the previous period, reflecting an increase[36] - Basic earnings per share increased to 0.36 from 0.35, while diluted earnings per share remained at 0.35[36] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 87.41%, amounting to ¥19,853,090.75 compared to ¥157,685,994.56 in the same period last year[3] - Cash received from sales decreased by 37.52% to ¥251,789,957.18, indicating a reduction in cash inflow from sales[10] - Cash flow from operating activities generated a net amount of 19,853,090.75, down from 157,685,994.56 in the previous period[37] - The cash and cash equivalents at the end of the period amounted to 691,525,233.54, down from 787,586,776.51 in the previous period[43] - The company received cash from borrowings amounting to 244,752,383.66, compared to 80,141,000.00 in the previous period[43] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,835,862,931.48, reflecting a growth of 9.38% from ¥3,506,922,491.19 at the end of the previous year[3] - Total liabilities rose to ¥1,129,809,341.60, up from ¥879,208,383.78, indicating a significant increase of 28.5%[28] - The company's equity attributable to shareholders reached ¥2,502,236,633.17, an increase from ¥2,427,424,730.19, marking a growth of 3.1%[28] - Total current assets reached CNY 2,001,628,652.05, an increase from CNY 1,804,007,753.77 at the beginning of the year, reflecting a growth of approximately 10.95%[22] - Non-current assets totaled CNY 1,301,000,000.00, with fixed assets valued at CNY 874,355,977.65, up from CNY 596,164,848.68[22] Shareholder Information - The company reported a total of 27,724 common shareholders at the end of the reporting period[15] - The largest shareholder, Yang Minmin, holds 20.68% of the shares, totaling 41,307,019 shares[15] - The company has a total of 36,578,332 restricted shares, with 595,875 shares released during the period[19] - The company plans to unlock 25% of the restricted shares annually based on the previous year's holdings[19] Operational Changes - The company's accounts receivable increased by 30.52%, reaching ¥262,707,551.34 due to expanded sales and revenue growth[7] - The company experienced a 117.41% increase in taxes and surcharges, amounting to ¥1,604,640.25, in line with the company's expanded scale[10] - The company invested ¥792,287,726.31 in new financial products, a decrease of 37.10% compared to the previous period, reflecting a reduction in cash scale[10] - Research and development expenses for the current period were ¥27,526,324.50, a decrease of 6.0% from ¥29,415,589.37 in the previous period[32] - The company is actively pursuing market expansion and new product development strategies[21] Investment Activities - Cash inflow from investment activities totaled 771,161,653.00, compared to 653,584,897.10 in the previous period[40] - Cash outflow from investment activities was 946,517,606.70, down from 1,318,987,083.86 in the previous period[40] - The company reported a financial expense of ¥122,095.61, compared to a financial income of ¥9,516,129.79 in the previous period[32] - The deferred income tax assets increased to ¥17,507,343.27 from ¥15,095,741.19, showing a growth of 16.0%[28]